Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05717790Recruiting
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of nimotuzumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Primary endpoint: Overall Survival at 5 years. Started Dec 2022; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05717790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717790.